Business & Finance
Stellar Biotechnologies incurs higher Q2 net loss of USD1.35m
8 May 2018 -

Immunotherapy company Stellar Biotechnologies Inc (Nasdaq:SBOT) stated on Monday that it recorded a net loss of USD1.35m (USD0.90 per basic share) for the three months ended 31 March 2018.

This marks a decline in earnings when compared with a net loss of USD1.10m (USD0.76 per basic share) for the second quarter of the prior year.

Total revenues were relatively flat at USD0.06m for the three months ended 31 March 2018 over the same period last year.

Research and development (R&D) expenses of USD0.49m were recorded for the three months ended 31 March 2018, an increase by USD0.16m over R&D of USD0.33m for the same period last year, primarily due to research and development activities intended to increase the scalability and throughput capacity of existing manufacturing systems.

Login
Username:

Password: